查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1876600

数位表型分析市场机会、成长驱动因素、产业趋势分析及预测（2025-2034年）

Digital Phenotyping Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年全球数位表型市场价值为 15 亿美元，预计到 2034 年将以 9.7% 的复合年增长率增长至 38 亿美元。

数位表型市场 - IMG1

慢性病和精神健康问题的日益增多，以及智慧型手机和穿戴式健康设备的广泛普及，推动了市场成长。这些技术透过感测器被动地、持续地收集资料，追踪运动、心率、睡眠模式和位置​​。收集到的资料构成了数位表型系统的基础，支持健康监测和行为分析。人工智慧 (AI) 和机器学习 (ML) 的日益融合，透过实现预测分析、个人化治疗和疾病早期检测，进一步改变了市场格局。此外，数位表型透过行动装置互动、语音和活动资料捕捉人类行为的细微变化，正在重新定义行为研究和临床试验。这一新兴领域正在革新医疗保健，提供以往难以客观衡量的患者健康和生活方式模式的洞察。

市场范围
起始年份 2024
预测年份 2025-2034
起始值 15亿美元
预测值 38亿美元
复合年增长率 9.7%

2024年，软体领域占据43.3%的市场份额，预计到2034年将达到17亿美元，复合年增长率（CAGR）为10.1%。此领域涵盖云端平台和本地部署平台。软体在数位表型分析中发挥着至关重要的作用，它能够利用智慧型手机和穿戴式感测器即时收集和分析行为及生理资料。这些系统中的人工智慧和机器学习技术有助于进行预测建模、异常检测和持续行为监测。该领域的成长动力源于其能够为临床医生和研究人员提供超越传统临床环境的可操作性见解，从而改善患者参与度和健康管理效果，并应用于心理和生理健康领域。

2024年，心理健康监测市场规模预计将达到4.555亿美元。焦虑症、忧郁症和躁郁症等心理健康问题的盛行率在全球范围内持续上升，加速了对可扩展、技术驱动心理健康解决方案的需求。新冠疫情的持续影响进一步加剧了这一需求，促使人们更多地采用能够进行持续客观监测的数位化工具。数位表型分析应用程式利用智慧型手机资料和人机互动来评估心理健康状况，从而提供早期预警讯号，提示可能出现的困扰或行为变化。这种方法透过提供经济实惠、远距且无歧视的替代方案，有助于弥合心理健康服务可近性方面的差距，取代传统的治疗模式。

预计到2024年，北美数位表型分析市场将占据44.6%的份额。该地区的领先地位得益于强大的医疗基础设施、智慧型手机的高普及率以及可穿戴技术的早期应用。北美企业正迅速将人工智慧和机器学习功能融入数位表型分析平台，实现个人化治疗方案的製定、预测性分析以及提升患者参与度。先进的技术生态系统和积极的医疗创新相结合，使该地区成为数位表型分析应用的关键成长中心。

全球数位表型分析市场的主要参与者包括 Akili Interactive Labs、AliveCor、Fitbit、罗氏、葛兰素史克、ActiGraph、HumanAPI、Mindstrong、Alphabet（Google）、Onnela Lab、诺华、赛诺菲、武田製药和辉瑞。数位表型分析市场的领导企业正采用多种策略来增强其竞争优势和市场地位。许多企业正在投资先进的人工智慧和机器学习演算法，以提升预测能力并提供个人化的健康洞察。各公司正在扩大与医疗服务提供者、研究机构和数位健康新创公司的策略合作，以加速资料整合和临床验证。此外，各公司也致力于产品多元化，提供基于云端和混合平台的服务，以满足不同终端用户的需求。

目录

第一章：方法论与范围

第二章：执行概要

第三章：行业洞察

  • 产业生态系分析
    • 每个阶段的价值增加
    • 影响价值链的因素
  • 产业影响因素
    • 成长驱动因素
      • 精神健康和慢性疾病盛行率不断上升
      • 智慧型手机和穿戴式装置的日益普及
      • 转向以价值为导向和预防性医疗的转变日益明显
      • 远距医疗和远距监测的日益普及
    • 产业陷阱与挑战
      • 资料隐私问题、监管挑战
      • 缺乏标准化
    • 市场机会
      • 拓展至临床试验及製药领域
      • 日益关注行为研究与人口健康分析
  • 成长潜力分析
  • 监管环境
    • 北美洲
      • 我们
      • 加拿大
    • 欧洲
    • 亚太地区
  • 技术格局
    • 当前技术趋势
    • 新兴技术
  • 未来市场趋势
  • 波特的分析
  • PESTEL 分析

第四章：竞争格局

  • 介绍
  • 公司市占率分析
    • 全球的
    • 北美洲
    • 欧洲
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 关键进展
    • 併购
    • 伙伴关係与合作
    • 新产品发布
    • 扩张计划

第五章：市场估算与预测：依组件划分，2021-2034年

  • 主要趋势
  • 硬体
    • 穿戴式装置
    • 生物感测器
    • 其他连接的设备
  • 软体
    • 基于云端的
    • 现场
  • 服务

第六章：市场估算与预测：依应用领域划分，2021-2034年

  • 主要趋势
  • 心理健康监测
  • 慢性病管理
  • 行为研究
  • 睡眠和运动分析
  • 神经退化性疾病
  • 其他应用

第七章：市场估算与预测：依最终用途划分，2021-2034年

  • 主要趋势
  • 医疗保健提供者
  • 付款人
  • 製药公司
  • 其他最终用途

第八章：市场估算与预测：依地区划分，2021-2034年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第九章：公司简介

  • Akili Interactive Labs
  • ActiGraph
  • AliveCor
  • Alphabet (Google)
  • F. Hoffmann-La Roche
  • Fitbit
  • GlaxoSmithKline
  • HumanAPI
  • Mindstrong
  • Novartis
  • Onnela lab
  • Pfizer
  • Sanofi
  • Takeda Pharmaceuticals
简介目录
Product Code: 15165

The Global Digital Phenotyping Market was valued at USD 1.5 billion in 2024 and is estimated to grow at a CAGR of 9.7% to reach USD 3.8 billion by 2034.

Digital Phenotyping Market - IMG1

Market growth is propelled by the increasing incidence of chronic diseases and mental health conditions, along with the widespread adoption of smartphones and wearable health devices. These technologies enable passive, continuous data collection through sensors that track movement, heart rate, sleep patterns, and location. The collected data form the foundation of digital phenotyping systems, supporting health monitoring and behavioral analysis. The growing integration of artificial intelligence (AI) and machine learning (ML) is further transforming the market by enabling predictive analytics, personalized treatments, and early disease detection. Additionally, digital phenotyping is redefining behavioral research and clinical trials by capturing subtle changes in human behavior through mobile device interactions, speech, and activity data. This evolving field is revolutionizing healthcare by providing insights into patient health and lifestyle patterns that were previously difficult to measure objectively.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$1.5 Billion
Forecast Value$3.8 Billion
CAGR9.7%

The software segment held a 43.3% share in 2024 and is expected to reach USD 1.7 billion by 2034, growing at a CAGR of 10.1%. This segment includes both cloud-based and on-premises platforms. Software plays a critical role in digital phenotyping by enabling the real-time collection and analysis of behavioral and physiological data using smartphone and wearable sensors. AI and ML technologies within these systems facilitate predictive modeling, anomaly detection, and continuous behavioral monitoring. The segment's growth is driven by its ability to provide actionable insights for clinicians and researchers beyond traditional clinical settings, improving patient engagement and health management outcomes across both mental and physical health applications.

The mental health monitoring segment captured USD 455.5 million in 2024. The prevalence of mental health disorders such as anxiety, depression, and bipolar disorder continues to rise worldwide, accelerating the need for scalable, technology-driven mental health solutions. The lingering effects of the COVID-19 pandemic have amplified this demand, leading to increased adoption of digital tools that allow for continuous and objective monitoring. Digital phenotyping applications use smartphone-based data and human-computer interactions to evaluate mental well-being, providing early warning signs of distress or behavioral changes. This approach helps bridge accessibility gaps in mental healthcare by offering affordable, remote, and stigma-free alternatives to traditional therapy models.

North America Digital Phenotyping Market held a 44.6% share in 2024. The region's leadership is driven by strong healthcare infrastructure, high smartphone usage, and early adoption of wearable technologies. Companies in North America are rapidly incorporating AI and ML capabilities into digital phenotyping platforms, enabling personalized treatment planning, predictive analysis, and improved patient engagement. The combination of advanced technological ecosystems and proactive healthcare innovation has positioned the region as a key growth hub for digital phenotyping adoption.

Major players in the Global Digital Phenotyping Market include Akili Interactive Labs, AliveCor, Fitbit, F. Hoffmann-La Roche, GlaxoSmithKline, ActiGraph, HumanAPI, Mindstrong, Alphabet (Google), Onnela Lab, Novartis, Sanofi, Takeda Pharmaceuticals, and Pfizer. Leading companies in the Digital Phenotyping Market are employing multiple strategies to strengthen their competitive edge and market position. Many are investing in advanced AI and ML algorithms to enhance predictive capabilities and deliver personalized health insights. Firms are expanding strategic collaborations with healthcare providers, research organizations, and digital health startups to accelerate data integration and clinical validation. Companies are also focusing on product diversification, offering cloud-based and hybrid platforms to serve varied end users.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/Country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Component trends
    • 2.2.3 Application trends
    • 2.2.4 End Use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Value addition at each stage
    • 3.1.2 Factors affecting the value chain
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of mental health and chronic conditions
      • 3.2.1.2 Increasing proliferation of smartphones and wearables
      • 3.2.1.3 Growing shift toward value-based and preventive care
      • 3.2.1.4 Increasing expansion of telehealth and remote monitoring
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Data privacy concerns, regulatory challenges
      • 3.2.2.2 Lack of standardization
    • 3.2.3 Market opportunities
      • 3.2.3.1 Expansion into clinical trials and pharma
      • 3.2.3.2 Growing focus on behavioral research and population health analytics
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
      • 3.4.1.1 U.S.
      • 3.4.1.2 Canada
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Technology landscape
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Future market trends
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 Global
    • 4.2.2 North America
    • 4.2.3 Europe
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Merger and acquisition
    • 4.6.2 Partnership and collaboration
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Component, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Hardware
    • 5.2.1 Wearables
    • 5.2.2 Biosensors
    • 5.2.3 Other connected devices
  • 5.3 Software
    • 5.3.1 Cloud-based
    • 5.3.2 On-premises
  • 5.4 Services

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Mental health monitoring
  • 6.3 Chronic disease management
  • 6.4 Behavioral research
  • 6.5 Sleep and movement analysis
  • 6.6 Neurodegenerative disorders
  • 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Healthcare providers
  • 7.3 Payers
  • 7.4 Pharmaceutical companies
  • 7.5 Other End Use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Akili Interactive Labs
  • 9.2 ActiGraph
  • 9.3 AliveCor
  • 9.4 Alphabet (Google)
  • 9.5 F. Hoffmann-La Roche
  • 9.6 Fitbit
  • 9.7 GlaxoSmithKline
  • 9.8 HumanAPI
  • 9.9 Mindstrong
  • 9.10 Novartis
  • 9.11 Onnela lab
  • 9.12 Pfizer
  • 9.13 Sanofi
  • 9.14 Takeda Pharmaceuticals